Filing Flows › Companies › TransMedics Group › Timeline
TransMedics Group stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−29.3% to $88.24
TransMedics Group (TMDX) stock fell 29% over the last 252 sessions, to $88.24. On the way it reported 4 quarters, its insiders filed 8 open-market trades, and the company filed 3 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026 | Earnings | Earnings: beat the EPS estimate by 73.8% | −5.3% (−0.8% vs SPY) | — | — |
| Sep 11, 2026 | Insider buy | Weill David bought $109K | −3.4% (−4.3% vs SPY) | +1.9% (+1.3% vs SPY) | −8.8% (−11.8% vs SPY) |
| Sep 10, 2026 | 8-K | Directors and officers: departures, appointments, pay | −3.4% (−4.3% vs SPY) | +1.9% (+1.3% vs SPY) | −8.8% (−11.8% vs SPY) |
| Aug 4, 2026 | Earnings | Earnings: missed the EPS estimate by -7.4% | −1.0% (−2.8% vs SPY) | +8.1% (+6.1% vs SPY) | +0.8% (+0.3% vs SPY) |
| Jun 15, 2026 | Insider sale | Gunderson Thomas J. sold $722K | +3.5% (+1.7% vs SPY) | +3.5% (+2.9% vs SPY) | +3.3% (+1.4% vs SPY) |
| May 5, 2026 | Earnings | Earnings: missed the EPS estimate by -50.9% | −2.2% (−3.0% vs SPY) | −41.2% (−44.1% vs SPY) | −33.2% (−38.1% vs SPY) |
| Mar 4, 2026 | Insider sale | Weill David sold $524K | −0.2% (−0.9% vs SPY) | −12.3% (−11.9% vs SPY) | −38.8% (−35.3% vs SPY) |
| Mar 4, 2026 | Insider sale | Lovell Stephanie sold $178K | −0.2% (−0.9% vs SPY) | −12.3% (−11.9% vs SPY) | −38.8% (−35.3% vs SPY) |
| Mar 4, 2026 | Insider sale | Hernandez Gerardo sold $1.1M | −0.2% (−0.9% vs SPY) | −12.3% (−11.9% vs SPY) | −38.8% (−35.3% vs SPY) |
| Mar 2, 2026 | Insider sale | Ranganath Anil P. sold $120K | +1.2% (+1.1% vs SPY) | −11.4% (−9.4% vs SPY) | −43.2% (−35.2% vs SPY) |
| Mar 2, 2026 | Insider sale | Hernandez Gerardo sold $52K | +1.2% (+1.1% vs SPY) | −11.4% (−9.4% vs SPY) | −43.2% (−35.2% vs SPY) |
| Mar 2, 2026 | Insider sale | Corcoran Nicholas sold $413K | +1.2% (+1.1% vs SPY) | −11.4% (−9.4% vs SPY) | −43.2% (−35.2% vs SPY) |
| Feb 24, 2026 | Earnings | Earnings: beat the EPS estimate by 41.0% | +2.3% (+1.6% vs SPY) | +8.8% (+8.2% vs SPY) | −21.2% (−17.1% vs SPY) |
| Feb 4, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.6% (+0.7% vs SPY) | +2.2% (+1.4% vs SPY) | −0.6% (+1.5% vs SPY) |
| Jan 12, 2026 | 8-K | Material definitive agreement | −1.8% (−1.9% vs SPY) | +4.5% (+4.8% vs SPY) | +1.6% (+1.9% vs SPY) |
Insiders’ record here
In the year on the chart, TransMedics Group's insiders reported 1 open-market buy ($109K) and 7 sales ($3.1M). Of the 7 old enough to score, 6 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −62.9%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → TransMedics Group: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.